Enhancement of Antibody Responses toBacillus anthracisProtective Antigen Domain IV by Use of Calreticulin as a Chimeric Molecular Adjuvant
- 1 May 2008
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 76 (5) , 1952-1959
Abstract
The generation of protective humoral immune responses against the receptor-binding domain (domain IV) of protective antigen [PA(dIV)] ofBacillus anthracisrepresents a plausible approach against anthrax toxin. In the current study, we have developed a naked DNA vaccine encoding calreticulin (CRT) linked to PA(dIV) ofBacillus anthracis[CRT/PA(dIV)]. We transfected a human embryonic kidney cell line (HEK 293) with CRT/PA(dIV) DNA and performed Western blotting and confocal microscopy analysis. We found that linkage of CRT to PA(dIV) targets PA(dIV) to the endoplasmic reticulum, resulting in secretion of the chimeric CRT/PA(dIV) protein. We then evaluated the ability of CRT/PA(dIV) DNA to generate PA(dIV)-specific antibody responses and protective immunity against lethal anthrax toxin (PA plus lethal factor) challenge. We found that mice immunized with CRT/PA(dIV) DNA were capable of rapidly inducing significantly higher PA(dIV)-specific antibody responses than mice immunized with PA(dIV) DNA alone. Furthermore, we observed that this enhanced antibody response generated by CRT/PA(dIV) DNA was CD4 dependent, since CD4 knockout mice demonstrated a significant reduction in antibody responses. In addition, analysis of the titers and avidity maturation of the induced PA-specific antibodies revealed that vaccination with CRT/PA(dIV) DNA vaccine accelerated the avidity maturation of antibodies to PA(dIV) compared to vaccination with PA(dIV) DNA. Importantly, the enhanced antibody responses correlated to protective immunity against lethal anthrax toxin challenge. Thus, DNA vaccines encoding CRT linked to PA(dIV) may dramatically enhance PA-specific protective antibody responses. Our results have significant clinical applications for biodefense against anthrax toxin.Keywords
This publication has 41 references indexed in Scilit:
- Enhancing DNA Vaccine Potency by Combining a Strategy to Prolong Dendritic Cell Life and Intracellular Targeting Strategies with a Strategy to Boost CD4 + T CellsHuman Gene Therapy, 2007
- High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex FormationAntimicrobial Agents and Chemotherapy, 2007
- Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cellsExpert Review of Vaccines, 2007
- A Monoclonal Antibody to Bacillus anthracis Protective Antigen Defines a Neutralizing Epitope in Domain 1Infection and Immunity, 2006
- Combining Anthrax Vaccine and Therapy: a Dominant-Negative Inhibitor of Anthrax Toxin Is Also a Potent and Safe Immunogen for VaccinesInfection and Immunity, 2005
- Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesisVaccine, 2005
- Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulinVaccine, 2004
- Comparison of HPV DNA vaccines employing intracellular targeting strategiesGene Therapy, 2004
- Molecular epidemiology of Burkholderia speciesFrontiers in Bioscience-Landmark, 2003
- Repeated DNA Vaccinations Elicited Qualitatively Different Cytotoxic T Lymphocytes and Improved Protective Antitumor EffectsJournal of Biomedical Science, 2002